For US Healthcare Professionals Only
Filter
Bimekizumab in Hidradenitis Suppurativa: Real-World Satisfaction Results from Hi-BEAT in the US
Bimekizumab Improves Patient-Reported Outcomes Regardless of Baseline DT Count: 3-Year BE HEARD Trial
Bimekizumab in Black/African American Hidradenitis Suppurativa Patients: 3-Year BE HEARD EXT Data
Bimekizumab in Black/African American Patients with Hidradenitis Suppurativa: 3-Year BE HEARD EXT Data
Bimekizumab vs Emerging and Existing Therapies in Moderate to Severe HS: a Network Meta-Analysis
Bimekizumab Improves HRQoL in Patients with Moderate to Severe HS: 3-Year BE HEARD EXT HiSQOL Data
Bridging Perspectives in HS: Key Learnings from HCP, Patient, and Caregiver Input at the HS Summit
HS PROGRESS Registry: Real-World Patient Characteristics and Unmet Needs
Bimekizumab Efficacy and Safety Over 4 Years in Patients with Moderate to Severe HS: Results from the BE HEARD EXT OLE2 in 4 Countries
Bimekizumab Efficacy and Safety Over 4 Years in Patients with Moderate to Severe HS: Results from the BE HEARD EXT OLE2 in 4 Countries